Published April 8, 2022
- CADTH recommends that pemigatinib should not be reimbursed by public drug plans for the treatment of adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma (CCA) with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement.
- The clinical evidence reviewed by CADTH was not strong enough to show whether treatment with pemigatinib benefits patients with CCA. It is not known if pemigatinib would lead to better outcomes for patients compared to treatments that are currently available.
- Patients identified a need for treatments that improve tumour response, delay disease progression, and improve quality of life. It is not clear whether pemigatinib meets these needs.